The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Risk factors for venous thromboembolic events in pregnant patients with SCD
Lydia Pecker, MD, Johns Hopkins University School of Medicine, Baltimore, MD, discusses a retrospective study which investigated the risk factors for venous thromboembolic events (VTE) in pregnant patients with sickle cell disease (SCD). Of the 290 pregnancies included in the analysis, 7% had a reported VTE (deep vein thrombosis and/or pulmonary embolism) and several risk factors for a VTE during gestation were markers of disease severity, including history of VTE, hydroxyurea use, intrapartum painful events, and acute coronary syndrome. As thrombosis was associated with premature delivery and increased C-section rates, as well as the rate of VTE exceeding the American Society of Hematology threshold for initiating anticoagulation prophylaxis, it is necessary to address the unmet need for specific pregnancy guidelines in individuals with SCD. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Global Blood Therapeutics, Novo Nordisk
Research Funding: Alexion
